Launch date: 23rd July, 2021
COLLABORATING TO ACHIEVE UNIVERSAL HEALTH COVERAGE- Cross-sector partnerships to support healthcare system strengthening in Kenya
View the full report by clicking the “download” button below:
Welcome to Kenya Association of Pharmaceutical Industry
Contact Us : email@example.com I Member Login
Launch Date: 23rd July, 2021
KAPI was honored to host several stakeholders during the launch of the KAPI Report on Friday 23rd July, 2021. Among those who graced our occasion, The CAS, Ministry of Health, Dr. Mercy Mwangangi, The CEO, Pharmacy and Poisons Board, Dr. Fred Siyoi, Assistant Director General, IFPMA, Greg Perry, The Chair, Kenya Medical Practitioners and Dentists Council (KMPDC), Dr. Eva Njenga, The Chair AEC Dr. Karim Bendhaou, Cluster Head, Novartis East Africa, Anthony Mwangi, all highlighted on the progress that has been made by government and different sectors towards UHC. They also emphasized their commitment to partner with the industry and other sectors in order to strengthen the healthcare system and make UHC a reality in Kenya.
In the words of The KAPI Chair, Willy Soriney, “KAPI remains committed to work with government and other stakeholders to evolve the health systems towards an envisioned ideal as espoused in the governments’ UHC Agenda”
You may download the full report by clicking “download” below.
15th January 2021
The Kenya Association of Pharmaceutical Industry (KAPI) is a membership organization, established in the late 1960s, representing biopharmaceutical manufacturers (or their local representatives) that through research invent and develop medicines and technologies (e.g., Biopharmaceuticals, Vaccine Healthcare, Medical devices, Diagnostics) that significantly improve people’s lives. KAPI represents the industry voice and promotes efficiency in the pharmaceutical industry to ensure that medical products and healthcare technologies of the highest quality can be readily available for diagnosis, prevention and treatment of diseases.
This is a roundup of news allied to the biopharmaceutical industry with a bearing on our mission to improve access to lifesaving health products and technologies for positive health outcomes.
With a macroeconomic growth of between five and 10 per cent, according to the 2016-2017 Comesa biennial report, Kenya was recognised as one of the fastest growing countries in the world. It has become a business hub in East Africa, with diverse investments by foreign firms keen to penetrate the lucrative regional markets.
The pharmaceutical industry is no.exception.
International media focus on promotion practices has resulted in increased scrutiny of the practice world over on the operations of the Pharmaceutical and Medical Devices industry. Enactment of anti- corruption and anti-bribery laws that have a wider jurisdiction of enforcement, in the United states, United Kingdom amongst other countries have highlighted the need to transparency in operation across many countries. Kenya has also enacted anti-corruption laws that have created the need for more transparency and accountability in interactions with healthcare professionals and the public.